The Global Harmonization Task Force (GHTF) released a new guidance Feb. 5 designed to help manufacturers do a better job with the often fraught task of ensuring supplier quality. "Quality Management System - Medical Devices - Guidance on the Control of Products and Services Obtained From Suppliers" advises companies to control and audit "sub-tier" suppliers when necessary, noting that firms may need to "extend control beyond the first-tier supplier due to the effects changes made by a second- or third-tier supplier may have on the supplied product/part or the medical device." The document also instructs companies to consider various risks - such as the complexity and criticality of supplied components - when selecting a vendor. Further, "information about potential suppliers (such as technical, financial, continuity of supply, etc.) should be used to determine additional potential risks." FDA GMP/quality systems expert Kim Trautman says FDA intends eventually to adopt the GHTF document as an agency guidance to help industry better carry out Quality System Regulation requirements related to supplier control ("The Silver Sheet" May 2008). The GHTF document can be found at www.ghtf.org/documents/sg3/sg3final-N17.pdf
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.
Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.
In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul
Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.
In revising the foundations of EU product legislation, the European Commission aims to increase harmonization, cut regulatory burdens and promote digital tools to boost compliance and safety.
The medtech M&A landscape is experiencing a resurgence fueled by significant capital from private equity and venture firms, says Alex Wakefield, CRO of AcuityMD. Building strong relationships with physicians remains crucial in medtech, and defining an exit strategy early is imperative.